Yesterday's news was all about Medtronic's (NYSE:MDT) proposed transaction with Covidien (NYSE:COV). But let's take a brief look at whether this tie-up implicates Medtronic as a potentially attractive investment. Of course, there were already reasons to like Medtronic -- it has significant exposure to international and emerging markets, and don't forget that the slow-growing med-tech behemoth is a dividend aristocrat (with at least 25 consecutive years of dividend increases to earn that designation). So, do the shares look attractive?

In the video below, health care analysts Michael Douglass and David Williamson give their thoughts on the investing case for Medtronic.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.